Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

NEXT STORY
Biomerica Signs Exclusive Distribution Agreement in Canada for its New and Proprietary Helicobacter Pylori (H. pylori) Test, hp+detect™
PREV STORY
Scipher Medicine Announces PrismRA® Met Primary and Secondary Endpoints in Prospective Observational Study Predicting Inadequate Response to World’s Largest-Selling Drug Class
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

NEXT STORY
Biomerica Signs Exclusive Distribution Agreement in Canada for its New and Proprietary Helicobacter Pylori (H. pylori) Test, hp+detect™
PREV STORY
Scipher Medicine Announces PrismRA® Met Primary and Secondary Endpoints in Prospective Observational Study Predicting Inadequate Response to World’s Largest-Selling Drug Class
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Reliq Health Technologies, Inc. Announces New Contract with US Nephrology Clinic to Provide iUGO Care to Chronic Kidney Disease Patients

author_avatar
NASDAQ Market News

Altimmune Announces Pre-Clinical Data From its SparVax-L Anthrax Vaccine Program

Single dose of vaccine showed 67% survival rate and 100% survival rate after two ...

author_avatar
NASDAQ Market News

Mr. Ron Andrews joins Precipio’s Board of Directors

author_avatar
NASDAQ Market News